Lu­mi­cell nabs FDA ap­proval for drug-de­vice breast can­cer de­tec­tion sys­tem

The Mass­a­chu­setts-based biotech Lu­mi­cell won FDA ap­proval on Thurs­day for its drug-de­vice com­bi­na­tion prod­uct used to help de­tect resid­ual can­cer in breast can­cer pa­tients, the FDA an­nounced.

The com­bo of both the op­ti­cal imag­ing agent peg­uli­cia­n­ine and the com­pa­ny’s Di­rect Vi­su­al­iza­tion Sys­tem or an­oth­er flu­o­res­cence imag­ing de­vice al­lows sur­geons to scan for and re­move resid­ual can­cer that may oth­er­wise go un­de­tect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER